Onyx’s Kyprolis Heads To ODAC With Open-label Trial; Will Desperation Outweigh Doubts?
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx is relying on a single open-label single-arm Phase IIb trial of Kyprolis (carfilzomib) in patients with relapsed and refractory myeloma, which resulted in an overall response rate of 24%